Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.

By Mitsuhiro Watanabe, Sander M. Houten, Li Wang, A. Moschetta, D. Mangelsdorf, R. Heyman, D. Moore, Johan Auwerx. Journal of Clinical Investigation, 2004

1,321 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/64258e820e8c0afbc191b9b5c4287bc1635977ac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. J. Y. Chiang
2. P. Tontonoz
3. A. Calkin
4. Tiangang Li
5. D. Mangelsdorf
6. Almut Heinken
7. R. Evans
8. G. Svegliati-Baroni

In Oncology

1. J. Y. Chiang
2. P. Tontonoz
3. Tiangang Li
4. A. Calkin
5. D. Mangelsdorf
6. Johan Auwerx
7. David S. Wishart

In Surgery

1. J. Y. Chiang
2. P. Tontonoz
3. A. Calkin
4. D. Mangelsdorf
5. Tiangang Li
6. Johan Auwerx
7. G. Svegliati-Baroni
8. F. Marra

Citations in the corpus

• Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR (2012, background): “FXR reduces SREBP1C expression, which seems to occur via the induction of SHP, as it is not observed in Shp -null mic”
• Energy Metabolism in the Liver (2014, neutral): “SIRT1 deacetylates and inhibits SREBP-1c, suppressing lipogenesis in the liver (209, 269).”
• Bile Acid Signaling in Metabolic Disease and Drug Therapy (2014, background): “It was suggested that the FXR/SHP cascade might repress LXRa induction of SREBP-1c and lipogenesis (Watanabe et al., 2004).”
• TGR5-mediated bile acid sensing controls glucose homeostasis. (2009, background): “, 2006) and decreasing lipogenesis and VLDL production (Watanabe et al., 2004), thereby reducing hepatic glucose and fatty acid output, which in turn contributes to improved insulin sensitivity (Duran-Sandoval et al.”
• Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. (2016, methodology): “5% w/w cholic acid (CA) has been previously reported (Watanabe et al., 2006; Watanabe et al., 2004).”
• Lipotoxicity and the gut-liver axis in NASH pathogenesis. (2018, background): “The specific mechanisms involved in the triglyceride-lowering effect of BAs have been first identified a decade ago [137] when Watanabe demonstrated that hepatic FXR activation mediated by BAs could induce the expression of the atypical NR small”
• Gut microbiota functions: metabolism of nutrients and other food components (2017, background): “Through binding to these receptors, bile acids can regulate genes critical to their synthesis, conjugation, transport, and detoxification [75–77] as well as lipid [78, 79] and glucose metabolism [80, 81] and energy homeostasis [82].”
• Farnesoid X receptor is essential for normal glucose homeostasis. (2006, background): “Consistent with previous results (25), CA feeding also reduced serum triglyceride levels in the WT mice but not the FXR–/– mice (Figure 6D).”